IL6 and plasma cell myeloma: Further, IL-6 plays critical roles in the progression of non-small cell lung cancer (NSCLC) [25], and the increased serum concentrations in patients are associated with advanced tumor stages of several tumors (e.g., multiple myeloma, renal cell carcinoma, prostate cancer, breast and ovarian cancer) [41, 42].